Polypeptide-Coupled Small Molecule for SARS-CoV-2 PLpro Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-SARS-CoV-2 drugs have low specificity and unsatisfactory inhibitory effects due to their origins in treating HIV or other RNA viruses, and they suffer from low oral bioavailability and rapid mutation-driven drug resistance.
Innovation Solution
A polypeptide-coupled small molecule compound is developed by chemically linking a polypeptide with the amino acid sequence LXGG, specifically recognized and cleaved by coronavirus PLpro, with a small molecule compound capable of inhibiting PLpro activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target PLpro, then antiviral efficacy is improved, but cytotoxicity increases
Solution Approach 1:
The patent uses a polypeptide linker containing the LXGG sequence as an intermediary between the small molecule inhibitor and the target virus. The polypeptide specifically binds to PLpro through the LXGG sequence, delivering the small molecule inhibitor precisely to the viral protease while preventing the small molecule from directly contacting and damaging host cells, thus reducing cytotoxicity while maintaining antiviral efficacy
Solution Approach 2:
The invention creates a heterogenous structure where different parts have different functions: the polypeptide portion (with LXGG sequence) provides specific recognition and binding to PLpro, while the small molecule portion provides the inhibitory activity. This local differentiation allows the compound to exert antiviral effects selectively at the virus-protease interface without affecting host cell integrity
2Reliability
If existing anti-SARS-CoV-2 drugs are used, then viral replication is inhibited, but specificity is low due to origins in treating HIV or other RNA viruses
Solution Approach 1:
The patent designs a compound with localized specific recognition elements. The polypeptide portion containing the LXGG sequence is specifically recognized and cleaved by coronavirus PLpro, providing high specificity for SARS-CoV-2 and related coronaviruses. This specific recognition sequence is not present in HIV or other RNA viruses, allowing the drug to selectively target coronavirus PLpro while leaving other viral systems unaffected
Solution Approach 2:
The polypeptide linker acts as a specific intermediary that mediates recognition between the small molecule inhibitor and coronavirus PLpro. The LXGG sequence in the polypeptide is the specific recognition element that binds to PLpro's active site, ensuring the drug selectively targets coronavirus protease rather than other viral proteases, thereby achieving high specificity
3Device complexity
If single-target drugs are used, then drug development is simplified, but drug resistance occurs easily due to rapid SARS-CoV-2 mutation
Solution Approach 1:
The patent merges two functional elements into a single compound: the polypeptide recognition element (with LXGG sequence) and the small molecule inhibitor. This unified structure simultaneously provides specific target recognition and potent inhibitory activity, creating a multi-functional agent that can adapt to viral mutations while maintaining efficacy, thus preventing resistance without requiring complex multi-drug regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide-coupled small molecule compound effectively targets and inhibits PLpro, curbing viral replication with enhanced antiviral efficacy, improved solubility, and reduced cytotoxicity compared to existing inhibitors.
Implementation Method 1
the polypeptide with the amino acid sequence LXGG, specifically recognized and cleaved by coronavirus PLpro
Data Source
AI summary
A polypeptide-coupled small molecule compound and its antiviral applications are provided. The polypeptide-coupled small molecule compound is obtained by linking a polypeptide with a sequence X′nLXGG and a small molecule compound capable of inhibiting activity of papain-like protease (PLpro) of coronavirus through a chemical bond. The polypeptide with the sequence X′nLXGG is a polypeptide with a sequence LXGG at its carboxyl terminal, X and X′ are independently any amino acid, and n is an integer between 1-50. The structure of the small molecule compound capable of inhibiting the activity of PLpro contains an amino group or a hydroxyl group. The polypeptide-coupled small molecule compound can inhibit the PLpro of SARS-CoV-2 in a targeted manner, thereby inhibiting the polyprotein cleavage of coronavirus in the host, and achieving the purpose of inhibiting the replication of coronavirus in the host. It has the advantages of synergistic inhibition, low cytotoxicity and favorable solubility.